Published in J Hepatol on September 21, 2008
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
The Global Burden of Cancer 2013. JAMA Oncol (2015) 5.93
Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol (2010) 5.87
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. Cancer (2014) 2.26
KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol (2012) 2.10
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int (2015) 1.92
Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology (2012) 1.91
Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology (2014) 1.58
Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol (2009) 1.56
A population-based cohort study for the risk factors of HCC among hepatitis B virus mono-infected subjects in Japan. J Gastroenterol (2010) 1.53
Rates of cirrhosis and hepatocellular carcinoma in chronic hepatitis B and the role of surveillance: a 10-year follow-up of 673 patients. Eur J Gastroenterol Hepatol (2015) 1.47
Exosomes: small vesicles with big roles in hepatocellular carcinoma. Oncotarget (2016) 1.43
Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer (2012) 1.32
Seroprevalence of hepatitis B and C virus in HIV-1 and HIV-2 infected Gambians. Virol J (2010) 1.29
Dendritic cell regulation of carbon tetrachloride-induced murine liver fibrosis regression. Hepatology (2012) 1.24
Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma. World J Gastroenterol (2011) 1.21
Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in chronic hepatitis B. J Infect Dis (2011) 1.11
Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic. Dig Dis Sci (2009) 1.09
KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol (2016) 1.07
Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol Int (2010) 1.03
Significant association of different preS mutations with hepatitis B-related cirrhosis or hepatocellular carcinoma. J Gastroenterol (2010) 1.03
Cancer-associated fibroblasts from hepatocellular carcinoma promote malignant cell proliferation by HGF secretion. PLoS One (2013) 1.00
Pre-S deletion and complex mutations of hepatitis B virus related to young age hepatocellular carcinoma in Qidong, China. PLoS One (2013) 1.00
Sex differences in HIV RNA level and CD4 cell percentage during childhood. Clin Infect Dis (2011) 0.99
Molecular identification of hepatitis B virus genotypes/subgenotypes: revised classification hurdles and updated resolutions. World J Gastroenterol (2014) 0.98
Ultra-deep pyrosequencing analysis of the hepatitis B virus preCore region and main catalytic motif of the viral polymerase in the same viral genome. Nucleic Acids Res (2011) 0.97
Genotypes, mutations, and viral load of hepatitis B virus and the risk of hepatocellular carcinoma: HBV properties and hepatocarcinogenesis. Hepat Mon (2011) 0.95
Global gene expression profiling reveals SPINK1 as a potential hepatocellular carcinoma marker. PLoS One (2013) 0.95
Predictive value of alpha-fetoprotein in the long-term risk of developing hepatocellular carcinoma in patients with hepatitis B virus infection--results from a clinic-based longitudinal cohort. Eur J Cancer (2012) 0.94
Prevalence and Clinical and Immunoviralogical Profile of Human Immunodeficiency Virus-Hepatitis B Coinfection among Children in an Antiretroviral Therapy Programme in Benue State, Nigeria. ISRN Pediatr (2013) 0.92
Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. Br J Cancer (2013) 0.91
Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. J Natl Cancer Inst (2012) 0.90
Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues. World J Hepatol (2015) 0.89
Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. World J Gastroenterol (2013) 0.89
The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. Am J Pathol (2013) 0.89
Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy. World J Gastroenterol (2013) 0.89
Hepatitis B virus genetic variants: biological properties and clinical implications. Emerg Microbes Infect (2013) 0.88
Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study. World J Gastroenterol (2014) 0.88
Evaluation of the patient with hepatitis B. Hepatology (2009) 0.88
Prevention of hepatocellular carcinoma in patients with chronic hepatitis B. World J Gastrointest Pharmacol Ther (2014) 0.88
Independent factors and predictive score for extrahepatic metastasis of hepatocellular carcinoma following curative hepatectomy. Oncologist (2012) 0.86
Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort. Carcinogenesis (2011) 0.86
Serum ceruloplasmin levels correlate negatively with liver fibrosis in males with chronic hepatitis B: a new noninvasive model for predicting liver fibrosis in HBV-related liver disease. PLoS One (2013) 0.86
Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients. PLoS One (2013) 0.85
Epigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutrition. Nutrients (2014) 0.84
Transient elastography-based risk estimation of hepatitis B virus-related occurrence of hepatocellular carcinoma: development and validation of a predictive model. Onco Targets Ther (2013) 0.83
How grim is hepatocellular carcinoma? Ann Med Surg (Lond) (2014) 0.83
Personalized treatment of hepatitis B. Clin Mol Hepatol (2015) 0.83
Management of HBV and HBV/HDV-Associated Liver Cirrhosis. Visc Med (2016) 0.83
Hepatitis B virus genotype, mutations, human leukocyte antigen polymorphisms and their interactions in hepatocellular carcinoma: a multi-centre case-control study. Sci Rep (2015) 0.83
Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit. World J Gastroenterol (2014) 0.83
Epidemiology and molecular characterization of hepatitis B virus infection in isolated villages in the Western Brazilian Amazon. Am J Trop Med Hyg (2012) 0.83
Update on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection. Curr Hepat Rep (2011) 0.82
Geographic patterns of hepatocellular carcinoma mortality with exposure to iron in groundwater in Taiwanese population: an ecological study. BMC Public Health (2013) 0.82
The L60V variation in hepatitis B virus core protein elicits new epitope-specific cytotoxic T lymphocytes and enhances viral replication. J Virol (2013) 0.82
Acute and Chronic Toxicity of an Aqueous Fraction of the Stem Bark of Stryphnodendron adstringens (Barbatimão) in Rodents. Evid Based Complement Alternat Med (2013) 0.82
Risk Factors and Post-Resection Independent Predictive Score for the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma. PLoS One (2016) 0.81
Settling the "score" with liver cancer. J Hepatol (2008) 0.80
Hepatitis B virus genetic mutations and evolution in liver diseases. World J Gastroenterol (2014) 0.80
Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study. Am J Gastroenterol (2016) 0.79
Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir. World J Gastroenterol (2013) 0.79
Associations between pre-S deletion mutation of hepatitis B virus and risk of hepatocellular carcinoma in the Asian population: a meta-analysis. Med Sci Monit (2015) 0.78
Risk calculators for hepatocellular carcinoma in patients affected with chronic hepatitis B in Asia. World J Gastroenterol (2014) 0.78
Quantitative evaluation of hepatitis B virus mutations and hepatocellular carcinoma risk: a meta-analysis of prospective studies. Chin J Cancer Res (2015) 0.78
Epigenetic Activation of Wnt/β-Catenin Signaling in NAFLD-Associated Hepatocarcinogenesis. Cancers (Basel) (2016) 0.78
Optimal surveillance program for hepatocellular carcinoma - getting ready, but not yet. World J Hepatol (2015) 0.77
The Effect of HBV Genotype C on the Development of HCC Differs Between Wild-Type Viruses and Those With BCP Double Mutations (T(1762)A(1764)). Hepat Mon (2014) 0.77
Molecular prognostic prediction in liver cirrhosis. World J Gastroenterol (2015) 0.77
Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population. Cancer Prev Res (Phila) (2016) 0.77
Exploring risk factors of hepatitis B virus-associated hepatocellular carcinoma: prospective verse retrospective studies. J Gastroenterol (2010) 0.76
Risk prediction models for hepatocellular carcinoma in different populations. Chin J Cancer Res (2016) 0.76
Increased hepatocellular carcinoma risk in chronic hepatitis B patients with persistently elevated serum total bile acid: a retrospective cohort study. Sci Rep (2016) 0.75
Domain Analysis of Integrated Data to Reduce Cost Associated with Liver Disease. Stud Health Technol Inform (2015) 0.75
Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients. World J Gastroenterol (2016) 0.75
Prediction and prophylaxis of hepatocellular carcinoma occurrence and postoperative recurrence in chronic hepatitis B virus-infected subjects. World J Gastroenterol (2016) 0.75
The incidence rate over 10 years of naturally occurring, cancer related mutations in the basal core promoter of hepatitis B virus. Infect Genet Evol (2015) 0.75
A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation. Medicine (Baltimore) (2016) 0.75
Hepatitis B Virus Core Promoter Double Mutations (A1762T, G1764A) Are Associated with Lower Levels of Serum Dihydrolipoyl Dehydrogenase. Intervirology (2016) 0.75
The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy. Clin Mol Hepatol (2016) 0.75
Score model for predicting acute-on-chronic liver failure risk in chronic hepatitis B. World J Gastroenterol (2015) 0.75
Clinical Impact of Viral Load on the Development of Hepatocellular Carcinoma and Liver-Related Mortality in Patients with Hepatitis C Virus Infection. Gastroenterol Res Pract (2016) 0.75
Successful resection of hepatocellular cancer not amenable to Milan criteria and durable complete remission induced by systemic polichemotherapy after development of metastases - should we think about revising the current treatment guidelines in selected patients? World J Surg Oncol (2013) 0.75
Clinical implications of evolutionary patterns of homologous, full-length hepatitis B virus quasispecies in different hosts after perinatal infection. J Clin Microbiol (2014) 0.75
Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated? Curr Hepatol Rep (2017) 0.75
Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy. World J Gastroenterol (2013) 0.75
New perspectives of biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol (2016) 0.75
Comparison of FIB-4 index and aspartate aminotransferase to platelet ratio index on carcinogenesis in chronic hepatitis B treated with entecavir. J Cancer (2017) 0.75
Personalized management of hepatocellular carcinoma based on molecular information: future prospects. Clin Liver Dis (Hoboken) (2015) 0.75
Elevated liver fibrosis index FIB-4 is not reliable for HCC risk stratification in predominantly non-Asian CHB patients. Medicine (Baltimore) (2016) 0.75
A novel scoring system predicts adjuvant chemolipiodolization benefit for hepatocellular carcinoma patients after hepatectomy. Oncotarget (2016) 0.75
The correlation between serum HBsAg levels and viral loads depends upon wild-type and mutated HBV sequences rather than the HBeAg/anti-HBe status. J Med Virol (2015) 0.75
Clonorchis sinensis infection and co-infection with the hepatitis B virus are important factors associated with cholangiocarcinoma and hepatocellular carcinoma. Parasitol Res (2017) 0.75
Screening for hepatocellular carcinoma: patient selection and perspectives. J Hepatocell Carcinoma (2017) 0.75
Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection. Oncotarget (2017) 0.75
Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma. Am J Gastroenterol (2017) 0.75
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology (2005) 9.39
Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology (2003) 7.35
Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology (2010) 4.58
Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology (2003) 4.33
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology (2010) 3.57
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med (2015) 3.16
Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology (2007) 3.08
Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99
A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology (2002) 2.90
Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. Hepatology (2002) 2.85
HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology (2008) 2.84
A comparison of fibrosis progression in chronic liver diseases. J Hepatol (2003) 2.82
Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology (2003) 2.73
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology (2003) 2.64
Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon. J Virol (2005) 2.63
Helicobacter pylori in North and South America before Columbus. FEBS Lett (2002) 2.57
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2010) 2.32
Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells. J Biol Chem (2004) 2.32
Bottom-up histogenesis of colorectal adenomas: origin in the monocryptal adenoma and initial expansion by crypt fission. Cancer Res (2003) 2.24
Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol (2008) 2.24
A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J Virol (2009) 2.20
Classifying hepatitis B virus genotypes. Intervirology (2003) 2.20
High frequency of chimerism in transplanted livers. Hepatology (2003) 2.15
HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B. Clin Infect Dis (2013) 2.11
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl (2007) 2.08
What can be revealed by extending the sensitivity of HBsAg detection to below the present limit? J Hepatol (2008) 2.05
A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A (2002) 2.02
Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology (2003) 2.02
Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma. Gastroenterology (2012) 2.00
Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol (2009) 2.00
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med (2007) 1.92
Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology (2011) 1.89
HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology (2004) 1.83
Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J Virol (2002) 1.82
Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Clin Gastroenterol Hepatol (2013) 1.81
SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology (2004) 1.81
Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol (2010) 1.80
A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer (2002) 1.77
Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china. J Virol (2004) 1.76
Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther (2007) 1.76
Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology (2011) 1.74
Treatment of chronic hepatitis B: Evolution over two decades. J Gastroenterol Hepatol (2011) 1.73
Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol (2013) 1.73
Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol (2011) 1.73
The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol (2009) 1.72
A new subtype (subgenotype) Ac (A3) of hepatitis B virus and recombination between genotypes A and E in Cameroon. J Gen Virol (2005) 1.71
A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. Hepatology (2006) 1.65
Does the addition of endoscopic sphincterotomy to stent insertion improve drainage of the bile duct in acute suppurative cholangitis? Gastrointest Endosc (2003) 1.64
Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology (2010) 1.61
Live-donor liver transplantation for acute-on-chronic hepatitis B liver failure. Transplantation (2003) 1.61
A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. Hepatology (2012) 1.60
Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology (2006) 1.60
Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. Liver Int (2011) 1.60
Donor complications associated with living donor liver transplantation in Japan. Transplantation (2009) 1.60
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology (2002) 1.60
Development of a prediction model for 10-year risk of hepatocellular carcinoma in middle-aged Japanese: the Japan Public Health Center-based Prospective Study Cohort II. Prev Med (2012) 1.56
Reduction of C-reactive protein with isoflavone supplement reverses endothelial dysfunction in patients with ischaemic stroke. Eur Heart J (2008) 1.55
Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol (2004) 1.55
Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst (2003) 1.55
A population-based cohort study for the risk factors of HCC among hepatitis B virus mono-infected subjects in Japan. J Gastroenterol (2010) 1.53
Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol (2011) 1.53
Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system. J Clin Microbiol (2005) 1.53
Geographical and genetic diversity of the human hepatitis B virus. Hepatol Res (2010) 1.53
Virological and clinical implication of core promoter C1752/V1753 and T1764/G1766 mutations in hepatitis B virus genotype D infection in Mongolia. J Gastroenterol Hepatol (2008) 1.53